Clinical Trial Update: A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability, pharmacokinetic/pharmacodynamic, and QT interval study of HRS-5965 capsules in healthy subjects has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Anemia

Drugs mentioned

• HRS-5965

Snippet

Sponsor: Chengdu Suncadia Medicine Co., Ltd. | Conditions: Hemolytic Anemia | Phase 1 | Status: COMPLETED